

### AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below. A complete listing of the claims, including their current status identifier, is set forth below.

1. **(Currently amended)** A method ~~for identifying an anti-viral agent~~ comprising:  
contacting a hepatitis C virus (HCV) NS4B nucleotide binding motif (NBM)  
polypeptide with a candidate agent; and  
determining an effect of said candidate agent on a GTPase activity of said  
polypeptide.
2. (Canceled)
3. (Previously presented) The method of claim 1, wherein said method further  
comprises determining an effect of said candidate agent on nucleotide binding of said  
polypeptide.
4. (Canceled)
5. **(Currently amended)** The method of claim 1, wherein said method further  
comprises determining an effect of said candidate agent on [an] RNA binding ~~activity~~  
of said polypeptide.
6. (Original) The method of claim 1, wherein said candidate agent is a nucleotide  
analog.
7. (Original) The method of claim 6, wherein said nucleotide analog is a non-  
hydrolysable nucleotide.

8. (Currently amended) The method of claim 1, further comprising determining an effect of said candidate agent on replication of HCV.
9. (Currently amended) The method of claim 8 ~~claim 4~~, wherein said HCV is a subgenomic or full length HCV replicon.
10. (Currently amended) The method of claim 8 ~~claim 1~~, further comprising testing HCV replication in a huh7 cell.
11. (Withdrawn) A method for modulating NS4B protein activity, said method comprising:
  - contacting said NS4B protein with a modulatory agent in an amount sufficient to modulate a GTPase activity of said NS4B protein.
12. (Withdrawn) A method of inhibiting HCV replication in a cell, comprising:
  - contacting a cell infected with HCV with an NS4B polypeptide inhibitor, wherein said contacting inhibits a GTPase activity of said NS4B polypeptide of said HCV and thereby inhibits HCV replication in said cell.
13. (Withdrawn) The method of claim 12, wherein said HCV is an HCV subgenomic replicon.
14. (Withdrawn) The method of claim 12, wherein said cell is a huh7 cell.
15. (Withdrawn) A polynucleotide encoding a HCV NS4B protein with reduced nucleotide binding activity.
16. (Withdrawn) The polynucleotide of claim 15, wherein said polynucleotide encodes a polypeptide comprising the sequence  $X_1X_2X_3X_4X_5X_6X_7$ , where  $X_1$  is an amino acid other than Gly,  $X_2$  is an amino acid other than Ser or Gly,  $X_3$  is an amino acid other

than Ile or Val, X<sub>4</sub> is an amino acid other than Gly, X<sub>5</sub> is an amino acid other than Leu or Ile, X<sub>6</sub> is an amino acid other than Gly and X<sub>7</sub> is an amino acid other than Lys or Arg.

17. (Withdrawn) A virus particle containing the polynucleotide of claim 15.
18. (Withdrawn) A method of treating a subject for hepatitis C, comprising:  
administering to said subject an agent that inhibits a GTPase of an HCV NS4B polypeptide in an amount effective for the treatment of said subject.
19. (Withdrawn) The method of claim 18, wherein said subject is a human subject.
20. (Withdrawn) The method of claim 18, wherein said agent is administered in combination with another anti-HCV agent.
21. (Withdrawn) The method of claim 20, wherein said agent is ribavirin or interferon.
22. **(New)** The method of claim 8, wherein said method comprises assaying said candidate agent on HCV replication in a liver cell line or primary liver cell.
23. **(New)** The method of claim 9, wherein said HCV is live virus or a replicon thereof.